Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.

@article{Abel2016IntegratingFC,
  title={Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.},
  author={Gregory Alan Abel and Rena Buckstein},
  journal={American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
  year={2016},
  volume={36},
  pages={
          e337-e344
        }
}
Myelodysplastic syndromes (MDS) are a group of acquired hematopoietic stem cell disorders that manifest with progressive bone marrow failure and have a propensity to transform into leukemia. Although an increase in biologic understanding of MDS has led to improved patient risk stratification and prognostication, advances in treatment have lagged behind. While hematopoietic cell transplantation (HCT) is a potentially curative option for some, most affected patients continue to be treated with… CONTINUE READING